Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Atypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.

Ceribelli A, Krzyszczak ME, Li Y, Ross SJ, Chan JY, Chan EK, Burlingame RW, Webb TT, Bubb MR, Sobel ES, Reeves WH, Satoh M.

Arthritis Res Ther. 2011 Jul 22;13(4):R119. doi: 10.1186/ar3422.

2.

Coexistence of anti-RNA polymerase III and anti-U1RNP antibodies in patients with systemic lupus erythematosus: two cases without features of scleroderma.

Satoh M, Vazquez-Del Mercado M, Krzyszczak ME, Li Y, Ceribelli A, Burlingame RW, Webb TT, Sobel ES, Reeves WH, Chan EK.

Lupus. 2012 Jan;21(1):68-74. doi: 10.1177/0961203311422712. Epub 2011 Oct 24.

3.

Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies.

Yamasaki Y, Honkanen-Scott M, Hernandez L, Ikeda K, Barker T, Bubb MR, Narain S, Richards HB, Chan EK, Reeves WH, Satoh M.

Arthritis Rheum. 2006 Sep;54(9):3051-6.

4.

Analysis of autoantibodies against RNA polymerases using immunoaffinity-purifed RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay.

Chang M, Wang RJ, Yangco DT, Sharp GC, Komatireddy GR, Hoffman RW.

Clin Immunol Immunopathol. 1998 Oct;89(1):71-8.

PMID:
9756726
6.

Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA.

Santiago M, Baron M, Hudson M, Burlingame RW, Fritzler MJ.

J Rheumatol. 2007 Jul;34(7):1528-34. Epub 2007 Jun 15.

PMID:
17610318
7.

Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma.

Faucher B, Stein P, Granel B, Weiller PJ, Disdier P, Serratrice J, Harlé JR, Durand JM, Frances Y, Guis S, Pham T, Bardin N, Sanmarco M.

Eur J Intern Med. 2010 Apr;21(2):114-7. doi: 10.1016/j.ejim.2010.01.004. Epub 2010 Feb 8.

PMID:
20206882
8.

Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma.

Moinzadeh P, Fonseca C, Hellmich M, Shah AA, Chighizola C, Denton CP, Ong VH.

Arthritis Res Ther. 2014 Feb 14;16(1):R53. doi: 10.1186/ar4486.

9.

Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.

Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, Roddy J, Nash P, Sturgess A, Proudman S, Stevens W.

Arthritis Res Ther. 2011;13(6):R211. doi: 10.1186/ar3544. Epub 2011 Dec 22.

10.

Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis.

Villalta D, Morozzi G, Tampoia M, Alpini C, Brusca I, Salgarolo V, Papisch W, Bizzaro N.

Clin Chim Acta. 2010 May 2;411(9-10):710-3. doi: 10.1016/j.cca.2010.01.037. Epub 2010 Feb 4.

PMID:
20138166
11.

Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.

Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M, Zochling J, Sahhar J, Nash P, Roddy J, Hill C, Nikpour M, Stevens W, Proudman SM, Walker JG.

Arthritis Rheumatol. 2015 Dec;67(12):3234-44. doi: 10.1002/art.39316.

12.

Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis.

Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr.

Arthritis Rheum. 2005 Aug;52(8):2425-32.

13.

Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis.

Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ.

Clin Exp Immunol. 1999 Aug;117(2):395-402.

14.

Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies.

Hamaguchi Y, Kodera M, Matsushita T, Hasegawa M, Inaba Y, Usuda T, Kuwana M, Takehara K, Fujimoto M.

Arthritis Rheumatol. 2015 Apr;67(4):1045-52. doi: 10.1002/art.38994.

15.

Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.

Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, Goulet JR, Rich E, Grodzicky T, Raymond Y, Senécal JL.

Arthritis Rheum. 2008 Dec;58(12):3902-12. doi: 10.1002/art.24038.

16.

Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies.

Motegi S, Toki S, Yamada K, Uchiyama A, Ishikawa O.

J Dermatol. 2015 Feb;42(2):189-92. doi: 10.1111/1346-8138.12722. Epub 2014 Dec 6.

PMID:
25483258
17.

A case of renal crisis in a Korean scleroderma patient with anti-RNA polymerase I and III antibodies.

Kang EH, Im CH, Kim SH, Chung JR, Lee EY, Kim DJ, Lee EB, Song YW.

J Korean Med Sci. 2006 Dec;21(6):1121-3.

18.

Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study.

Satoh M, Krzyszczak ME, Li Y, Ceribelli A, Ross SJ, Chan EK, Segal MS, Bubb MR, Sobel ES, Reeves WH.

Arthritis Res Ther. 2011 May 10;13(3):R73. doi: 10.1186/ar3334.

19.

Serologic profile and mortality rates of scleroderma renal crisis in Italy.

Codullo V, Cavazzana I, Bonino C, Alpini C, Cavagna L, Cozzi F, Del Papa N, Franceschini F, Guiducci S, Morozzi G, Ruffatti A, Ferri C, Giacomelli R, Matucci-Cerinic M, Valentini G, Montecucco C.

J Rheumatol. 2009 Jul;36(7):1464-9. doi: 10.3899/jrheum.080806. Epub 2009 Jun 1.

PMID:
19487262
20.

HLA class II alleles in systemic sclerosis patients with anti-RNA polymerase I/III antibody: associations with subunit reactivities.

Kuwana M, Pandey JP, Silver RM, Kawakami Y, Kaburaki J.

J Rheumatol. 2003 Nov;30(11):2392-7.

PMID:
14677183

Supplemental Content

Support Center